The 20 years transition of clinical characteristics and metabolic risk factors in primary liver cancer patients from China
BackgroundThe clinical characteristics of primary liver cancer (PLC) patients are changing, maybe due to hepatitis viral vaccination and lifestyle changes, etc. The linkage between these changes and outcomes among these PLCs has not yet been fully elucidated.MethodsIt was identified total of 1691 PL...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-03-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2023.1109980/full |
| _version_ | 1797871439528853504 |
|---|---|
| author | Yezhou Ding Mingyang Feng Di Ma Gangde Zhao Xiaolin Wang Baoyan An Yumin Xu Shike Lou Lanyi Lin Qing Xie Kehui Liu Shisan Bao Hui Wang |
| author_facet | Yezhou Ding Mingyang Feng Di Ma Gangde Zhao Xiaolin Wang Baoyan An Yumin Xu Shike Lou Lanyi Lin Qing Xie Kehui Liu Shisan Bao Hui Wang |
| author_sort | Yezhou Ding |
| collection | DOAJ |
| description | BackgroundThe clinical characteristics of primary liver cancer (PLC) patients are changing, maybe due to hepatitis viral vaccination and lifestyle changes, etc. The linkage between these changes and outcomes among these PLCs has not yet been fully elucidated.MethodsIt was identified total of 1691 PLC cases diagnosed between 2000 ~ 2020. Cox proportional hazards models were utilized to determine the connections between the clinical presentations and their close risk factor(s) from PLC patients.ResultsThe average age of PLC patients increased gradually from 52.74 ± 0.5 years in 2000 ~ 2004 to 58.63 ± 0.44 years in 2017 ~ 2020, accompanied by an increased proportion of females from 11.11% to 22.46%, and non-viral hepatitis-related PLC was raised from 1.5% to 22.35%. 840 (49.67%) PLC patients with alpha-fetoprotein (AFP) < 20ng/mL (AFP-negative). The mortality was 285 (16.85%) or 532 (31.46%) PLC patients with alanine transaminase (ALT) between 40 ~ 60 IU/L or ALT > 60 IU/L. The PLC patients with pre-diabetes/diabetes or dyslipidemia also increased from 4.29% or 11.1% in 2000 ~ 2004 to 22.34% or 46.83% in 2017 ~ 2020. The survival period of the PLC patients with normoglycemia or normolipidemic was 2.18 or 3.14 folds longer than those patients with pre-diabetes/diabetes or hyperlipidemia (P<0.05).ConclusionsIt was gradually increased that age, the proportion of females, non-viral hepatitis-related causes, AFP-negative, and abnormal glucose/lipids among PLC patients. Proper control of glucose/lipids or ALT may improve the prognosis of PLCs. |
| first_indexed | 2024-04-10T00:43:01Z |
| format | Article |
| id | doaj.art-87663128b2e848ffaafdda2a6b986ec2 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-10T00:43:01Z |
| publishDate | 2023-03-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-87663128b2e848ffaafdda2a6b986ec22023-03-14T05:11:18ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2023-03-011310.3389/fonc.2023.11099801109980The 20 years transition of clinical characteristics and metabolic risk factors in primary liver cancer patients from ChinaYezhou Ding0Mingyang Feng1Di Ma2Gangde Zhao3Xiaolin Wang4Baoyan An5Yumin Xu6Shike Lou7Lanyi Lin8Qing Xie9Kehui Liu10Shisan Bao11Hui Wang12Department of Infectious Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaDepartment of Infectious Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaDepartment of General Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaDepartment of Infectious Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaDepartment of Infectious Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaDepartment of Infectious Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaDepartment of Infectious Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaDepartment of Infectious Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaDepartment of Infectious Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaDepartment of Infectious Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaDepartment of Infectious Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaDepartment of Infectious Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaDepartment of Infectious Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaBackgroundThe clinical characteristics of primary liver cancer (PLC) patients are changing, maybe due to hepatitis viral vaccination and lifestyle changes, etc. The linkage between these changes and outcomes among these PLCs has not yet been fully elucidated.MethodsIt was identified total of 1691 PLC cases diagnosed between 2000 ~ 2020. Cox proportional hazards models were utilized to determine the connections between the clinical presentations and their close risk factor(s) from PLC patients.ResultsThe average age of PLC patients increased gradually from 52.74 ± 0.5 years in 2000 ~ 2004 to 58.63 ± 0.44 years in 2017 ~ 2020, accompanied by an increased proportion of females from 11.11% to 22.46%, and non-viral hepatitis-related PLC was raised from 1.5% to 22.35%. 840 (49.67%) PLC patients with alpha-fetoprotein (AFP) < 20ng/mL (AFP-negative). The mortality was 285 (16.85%) or 532 (31.46%) PLC patients with alanine transaminase (ALT) between 40 ~ 60 IU/L or ALT > 60 IU/L. The PLC patients with pre-diabetes/diabetes or dyslipidemia also increased from 4.29% or 11.1% in 2000 ~ 2004 to 22.34% or 46.83% in 2017 ~ 2020. The survival period of the PLC patients with normoglycemia or normolipidemic was 2.18 or 3.14 folds longer than those patients with pre-diabetes/diabetes or hyperlipidemia (P<0.05).ConclusionsIt was gradually increased that age, the proportion of females, non-viral hepatitis-related causes, AFP-negative, and abnormal glucose/lipids among PLC patients. Proper control of glucose/lipids or ALT may improve the prognosis of PLCs.https://www.frontiersin.org/articles/10.3389/fonc.2023.1109980/fullclinical traitsfetoproteinalanine transaminaseglycolipidliver cancer |
| spellingShingle | Yezhou Ding Mingyang Feng Di Ma Gangde Zhao Xiaolin Wang Baoyan An Yumin Xu Shike Lou Lanyi Lin Qing Xie Kehui Liu Shisan Bao Hui Wang The 20 years transition of clinical characteristics and metabolic risk factors in primary liver cancer patients from China Frontiers in Oncology clinical traits fetoprotein alanine transaminase glycolipid liver cancer |
| title | The 20 years transition of clinical characteristics and metabolic risk factors in primary liver cancer patients from China |
| title_full | The 20 years transition of clinical characteristics and metabolic risk factors in primary liver cancer patients from China |
| title_fullStr | The 20 years transition of clinical characteristics and metabolic risk factors in primary liver cancer patients from China |
| title_full_unstemmed | The 20 years transition of clinical characteristics and metabolic risk factors in primary liver cancer patients from China |
| title_short | The 20 years transition of clinical characteristics and metabolic risk factors in primary liver cancer patients from China |
| title_sort | 20 years transition of clinical characteristics and metabolic risk factors in primary liver cancer patients from china |
| topic | clinical traits fetoprotein alanine transaminase glycolipid liver cancer |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2023.1109980/full |
| work_keys_str_mv | AT yezhouding the20yearstransitionofclinicalcharacteristicsandmetabolicriskfactorsinprimarylivercancerpatientsfromchina AT mingyangfeng the20yearstransitionofclinicalcharacteristicsandmetabolicriskfactorsinprimarylivercancerpatientsfromchina AT dima the20yearstransitionofclinicalcharacteristicsandmetabolicriskfactorsinprimarylivercancerpatientsfromchina AT gangdezhao the20yearstransitionofclinicalcharacteristicsandmetabolicriskfactorsinprimarylivercancerpatientsfromchina AT xiaolinwang the20yearstransitionofclinicalcharacteristicsandmetabolicriskfactorsinprimarylivercancerpatientsfromchina AT baoyanan the20yearstransitionofclinicalcharacteristicsandmetabolicriskfactorsinprimarylivercancerpatientsfromchina AT yuminxu the20yearstransitionofclinicalcharacteristicsandmetabolicriskfactorsinprimarylivercancerpatientsfromchina AT shikelou the20yearstransitionofclinicalcharacteristicsandmetabolicriskfactorsinprimarylivercancerpatientsfromchina AT lanyilin the20yearstransitionofclinicalcharacteristicsandmetabolicriskfactorsinprimarylivercancerpatientsfromchina AT qingxie the20yearstransitionofclinicalcharacteristicsandmetabolicriskfactorsinprimarylivercancerpatientsfromchina AT kehuiliu the20yearstransitionofclinicalcharacteristicsandmetabolicriskfactorsinprimarylivercancerpatientsfromchina AT shisanbao the20yearstransitionofclinicalcharacteristicsandmetabolicriskfactorsinprimarylivercancerpatientsfromchina AT huiwang the20yearstransitionofclinicalcharacteristicsandmetabolicriskfactorsinprimarylivercancerpatientsfromchina AT yezhouding 20yearstransitionofclinicalcharacteristicsandmetabolicriskfactorsinprimarylivercancerpatientsfromchina AT mingyangfeng 20yearstransitionofclinicalcharacteristicsandmetabolicriskfactorsinprimarylivercancerpatientsfromchina AT dima 20yearstransitionofclinicalcharacteristicsandmetabolicriskfactorsinprimarylivercancerpatientsfromchina AT gangdezhao 20yearstransitionofclinicalcharacteristicsandmetabolicriskfactorsinprimarylivercancerpatientsfromchina AT xiaolinwang 20yearstransitionofclinicalcharacteristicsandmetabolicriskfactorsinprimarylivercancerpatientsfromchina AT baoyanan 20yearstransitionofclinicalcharacteristicsandmetabolicriskfactorsinprimarylivercancerpatientsfromchina AT yuminxu 20yearstransitionofclinicalcharacteristicsandmetabolicriskfactorsinprimarylivercancerpatientsfromchina AT shikelou 20yearstransitionofclinicalcharacteristicsandmetabolicriskfactorsinprimarylivercancerpatientsfromchina AT lanyilin 20yearstransitionofclinicalcharacteristicsandmetabolicriskfactorsinprimarylivercancerpatientsfromchina AT qingxie 20yearstransitionofclinicalcharacteristicsandmetabolicriskfactorsinprimarylivercancerpatientsfromchina AT kehuiliu 20yearstransitionofclinicalcharacteristicsandmetabolicriskfactorsinprimarylivercancerpatientsfromchina AT shisanbao 20yearstransitionofclinicalcharacteristicsandmetabolicriskfactorsinprimarylivercancerpatientsfromchina AT huiwang 20yearstransitionofclinicalcharacteristicsandmetabolicriskfactorsinprimarylivercancerpatientsfromchina |